deltatrials
Unknown NA INTERVENTIONAL NCT00252044

Pergolide for Cognitive Symptoms in Schizotypal Personality Disorder

The Dopaminergic System in Schizotypal Personality Disorder: Pergolide for Cognitive Symptoms in Schizotypal Personality Disorder

Sponsor: Bronx VA Medical Center

Conditions Other Personality Disorders Schizotypal Personality Disorder
Interventions Pergolide
Updated 5 times since 2017 Last updated: Nov 17, 2005 Started: Oct 31, 2000
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00252044, this NA trial focuses on Other Personality Disorders and Schizotypal Personality Disorder and remains ongoing. Sponsored by Bronx VA Medical Center, it has been updated 5 times since 2000, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotUnknown Status~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotUnknown Status~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotUnknown Status~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotUnknown~Sep 2024 – present · 22 months · monthly snapshotUnknown

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Unknown NA

  2. Jul 2024 — Sep 2024 [monthly]

    Unknown NA

    Status: Unknown Status → Unknown

  3. Jan 2021 — Jul 2024 [monthly]

    Unknown Status NA

  4. Jun 2018 — Jan 2021 [monthly]

    Unknown Status NA

  5. Jan 2017 — Jun 2018 [monthly]

    Unknown Status NA

    First recorded

Oct 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bronx VA Medical Center
Data source: Bronx VA Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations